Delving into the Latest Updates on DEG-6498 with Synapse

Overview

Basic Info

Drug Type

Molecular glue

Synonyms

ELAVL1 (Degron Therapeutics), ELAVL1 (达歌生物), DEG 6498

+ [1]

Target

ELAVL1

Action

inhibitors

Mechanism

ELAVL1 inhibitors(ELAV like RNA binding protein 1 inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [1]

Active Indication

Advanced Malignant Solid NeoplasmHepatocellular CarcinomaSolid tumor+ [2]

Inactive Indication-

Originator Organization

Degron Therapeutics Co. Ltd.

Active Organization

Degron Therapeutics Co. Ltd.

Hangzhou Dago Biomedical Technology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are:
* what is an appropriate dose to be given to participants?
* are the side effects of treatment manageable?
Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.

Start Date01 Nov 2025

Sponsor / Collaborator

Degron Therapeutics Co. Ltd.

CTR20254261

/ Not yet recruitingPhase 1

DEG6498 在实体瘤患者中的首次人体 I 期开放标签、多中心、剂量递增及扩展研究

[Translation] First-in-human, open-label, multicenter, dose-escalation and expansion study of DEG6498 in patients with solid tumors.

评价DEG6498口服给药的安全性/耐受性, 确定DEG6498单药的最大耐受剂量(MTD) 和/或推荐 II 期剂量(RP2D).

[Translation]

Evaluate the safety/tolerability of oral DEG6498, and determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of DEG6498 monotherapy.

Start Date-

Sponsor / Collaborator

Hangzhou Dago Biomedical Technology Co., Ltd.

100 Clinical Results associated with DEG-6498

Login to view more data

100 Translational Medicine associated with DEG-6498

Login to view more data

100 Patents (Medical) associated with DEG-6498

Login to view more data

100 Deals associated with DEG-6498

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Hangzhou Dago Biomedical Technology Co., Ltd.	04 Nov 2025
Hepatocellular Carcinoma	Phase 1	China	Degron Therapeutics Co. Ltd.	01 Nov 2025
Solid tumor	Phase 1	United States	Degron Therapeutics Co. Ltd.	-
Colorectal Cancer	Preclinical	China	Degron Therapeutics Co. Ltd.	31 May 2024
Glioblastoma	Preclinical	China	Degron Therapeutics Co. Ltd.	31 May 2024